{"id":466,"date":"2026-04-12T09:33:14","date_gmt":"2026-04-12T09:33:14","guid":{"rendered":"https:\/\/luciuspharmacy.com\/?post_type=product&p=466"},"modified":"2026-08-30T03:53:24","modified_gmt":"2026-08-30T03:53:24","slug":"lucivemu-vemurafenib-240-mgx56-tablets","status":"publish","type":"product","link":"https:\/\/luciuspharmacy.com\/fr\/product\/lucivemu-vemurafenib-240-mgx56-tablets\/","title":{"rendered":"LuciVemu"},"content":{"rendered":"

HIGHLIGHTS OF PRESCRIBING INFORMATION <\/strong><\/span><\/p>\n

These highlights do not include all the information needed to use LuciVemu safely and effectively. See full prescribing information for LuciVemu.<\/strong><\/span><\/p>\n

 <\/span><\/p>\n

INDICATIONS AND USAGE<\/strong><\/strong><\/span><\/p>\n

LuciVemu is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.  LuciVemu is indicated for the treatment of patients with ErdheimChester Disease with BRAF V600 mutation. <\/span><\/p>\n

Limitation of Use: LuciVemu is not indicated for treatment of patients with wild-type BRAF melanoma.<\/span><\/p>\n

 <\/span><\/p>\n

DOSAGE AND ADMINISTRATION <\/strong><\/strong><\/span><\/p>\n

\u00b7 Confirm the presence of BRAF V600E mutation in tumor specimens prior to initiation of treatment with LuciVemu. <\/span><\/p>\n

\u00b7 Recommended dose: 960 mg orally twice daily taken approximately 12 hours apart with or without a meal. <\/span><\/p>\n

 <\/span><\/p>\n

DOSAGE FORMS AND STRENGTHS <\/strong><\/strong><\/span><\/p>\n

Tablets: 240 mg\u00d756 tablets<\/span><\/p>\n

 <\/span><\/p>\n

CONTRAINDICATIONS <\/strong><\/strong><\/span><\/p>\n

None<\/span><\/p>\n

 <\/span><\/p>\n

WARNINGS AND PRECAUTIONS <\/strong><\/strong><\/span><\/p>\n

\u00b7 New Primary Cutaneous Malignancies: Perform dermatologic evaluations prior to initiation of therapy, every 2 months while on therapy, and for up to 6 months following discontinuation of LuciVemu. Manage with excision and continue treatment without dose adjustment. <\/span><\/p>\n

\u00b7 New Non-Cutaneous Squamous Cell Carcinoma: Evaluate for symptoms or clinical signs of new non-cutaneous SCC before initiation of treatment and periodically during treatment. <\/span><\/p>\n

\u00b7 Other Malignancies: Monitor patients receiving LuciVemu closely for signs or symptoms of other malignancies. <\/span><\/p>\n

\u00b7 Tumor Promotion in BRAF Wild-Type Melanoma: Increased cell proliferation can occur with BRAF inhibitors. <\/span><\/p>\n

\u00b7 Serious Hypersensitivity Reactions including anaphylaxis and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS Syndrome): Discontinue LuciVemu for severe hypersensitivity reactions.<\/span><\/p>\n

\u00b7 Severe Dermatologic Reactions, including Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Discontinue LuciVemu for severe dermatologic reactions. <\/span><\/p>\n

\u00b7 QT Prolongation: Monitor ECG and electrolytes before and during treatment. Withhold LuciVemu for QTc of 500 ms or greater. Correct electrolyte abnormalities and control for cardiac risk factors for QT prolongation. <\/span><\/p>\n

\u00b7 Hepatotoxicity: Measure liver enzymes and bilirubin before initiating LuciVemu and monitor monthly during treatment. <\/span><\/p>\n

\u00b7 Photosensitivity: Advise patients to avoid sun exposure. <\/span><\/p>\n

\u00b7 Serious Ophthalmologic Reactions: Monitor for signs and symptoms of uveitis. <\/span><\/p>\n

\u00b7 Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of the potential risk to the fetus and to use effective contraception. <\/span><\/p>\n

\u00b7 Radiation Sensitization and Radiation Recall: Severe cases have been reported.  <\/span><\/p>\n

\u00b7 Renal Failure: Measure serum creatinine before initiating LuciVemu and monitor periodically during treatment. <\/span><\/p>\n

\u00b7 Dupuytren\u2019s Contracture and plantar fascial fibromatosis: Events should be managed with dose reduction, treatment interruption, or treatment discontinuation. <\/span><\/p>\n

 <\/span><\/p>\n

ADVERSE REACTIONS <\/strong><\/strong><\/span><\/p>\n

Melanoma: Most common adverse reactions (\u2265 30%) are arthralgia, rash,alopecia, fatigue, photosensitivity reaction, nausea, pruritus, and skin papilloma. <\/span><\/p>\n

Erdheim-Chester Disease: Most common adverse reactions (>50%) are arthralgia, rash maculo-papular, alopecia, fatigue, electrocardiogram QT interval prolonged, and skin papilloma. <\/span><\/p>\n

 <\/span><\/p>\n

DRUG INTERACTIONS <\/strong><\/strong><\/span><\/p>\n

Avoid concomitant administration of LuciVemu with strong CYP3A4 inhibitors or inducers. <\/span><\/p>\n

CYP1A2 Substrates: LuciVemu can increase concentrations of CYP1A2 substrates. Avoid concomitant use of LuciVemu with CYP1A2 substrates with a narrow therapeutic window. If coadministration cannot be avoided, monitor closely for toxicities and consider dose reduction of CYP1A2 substrates.<\/span><\/p>\n

 <\/span><\/p>\n

USE IN SPECIFIC POPULATIONS <\/strong><\/strong><\/span><\/p>\n

Lactation: Do not breastfeed while taking LuciVemu.<\/span><\/p>\n

 <\/span><\/p>\n

Storage <\/strong><\/strong><\/span><\/p>\n

Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F), excursions permitted between 15\u00b0C and 30\u00b0C (59\u00b0F and 86\u00b0F) [see USP Controlled Room Temperature]. Protect from moisture. <\/span><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

LuciVemu is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.<\/p>","protected":false},"featured_media":1950,"comment_status":"open","ping_status":"closed","template":"","meta":{"advanced_seo_description":"","jetpack_seo_html_title":"","jetpack_seo_noindex":false,"jetpack_seo_schema_type":""},"product_brand":[],"product_cat":[55],"product_tag":[],"class_list":["post-466","product","type-product","status-publish","has-post-thumbnail","product_cat-melanoma","first","instock","shipping-taxable","purchasable","product-type-simple"],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/luciuspharmacy.com\/fr\/wp-json\/wp\/v2\/product\/466","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/luciuspharmacy.com\/fr\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/luciuspharmacy.com\/fr\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/luciuspharmacy.com\/fr\/wp-json\/wp\/v2\/comments?post=466"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/luciuspharmacy.com\/fr\/wp-json\/wp\/v2\/media\/1950"}],"wp:attachment":[{"href":"https:\/\/luciuspharmacy.com\/fr\/wp-json\/wp\/v2\/media?parent=466"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/fr\/wp-json\/wp\/v2\/product_brand?post=466"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/fr\/wp-json\/wp\/v2\/product_cat?post=466"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/fr\/wp-json\/wp\/v2\/product_tag?post=466"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}